CN104017054B - Per2蛋白激动剂多肽及其应用 - Google Patents
Per2蛋白激动剂多肽及其应用 Download PDFInfo
- Publication number
- CN104017054B CN104017054B CN201410288285.3A CN201410288285A CN104017054B CN 104017054 B CN104017054 B CN 104017054B CN 201410288285 A CN201410288285 A CN 201410288285A CN 104017054 B CN104017054 B CN 104017054B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- per2
- protein agonist
- tumor
- per2 protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 37
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 36
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 36
- 101001073216 Homo sapiens Period circadian protein homolog 2 Proteins 0.000 title claims abstract description 32
- 102100035787 Period circadian protein homolog 2 Human genes 0.000 title claims abstract description 31
- 229940076376 protein agonist Drugs 0.000 title claims description 19
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract description 29
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract description 14
- 201000004101 esophageal cancer Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 24
- 208000017897 Carcinoma of esophagus Diseases 0.000 abstract description 15
- 201000005619 esophageal carcinoma Diseases 0.000 abstract description 15
- 230000004083 survival effect Effects 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 abstract description 4
- 230000001629 suppression Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000009509 drug development Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- RUDRIZRGOLQSMX-IUCAKERBSA-N Gly-Met-Met Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(O)=O RUDRIZRGOLQSMX-IUCAKERBSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 1
- MLKVIVZCFYRTIR-KKUMJFAQSA-N Pro-Phe-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O MLKVIVZCFYRTIR-KKUMJFAQSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- YOSLMIPKOUAHKI-OLHMAJIHSA-N Thr-Asp-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O YOSLMIPKOUAHKI-OLHMAJIHSA-N 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical group O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410288285.3A CN104017054B (zh) | 2014-06-25 | 2014-06-25 | Per2蛋白激动剂多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410288285.3A CN104017054B (zh) | 2014-06-25 | 2014-06-25 | Per2蛋白激动剂多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104017054A CN104017054A (zh) | 2014-09-03 |
CN104017054B true CN104017054B (zh) | 2016-12-07 |
Family
ID=51434097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410288285.3A Expired - Fee Related CN104017054B (zh) | 2014-06-25 | 2014-06-25 | Per2蛋白激动剂多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104017054B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1283694A (zh) * | 1999-08-10 | 2001-02-14 | 中国医学科学院肿瘤医院肿瘤研究所 | 一种食管癌相关新基因 |
CN102119170A (zh) * | 2008-06-10 | 2011-07-06 | 肿瘤疗法科学股份有限公司 | Mybl2表位肽及包含它的疫苗 |
-
2014
- 2014-06-25 CN CN201410288285.3A patent/CN104017054B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1283694A (zh) * | 1999-08-10 | 2001-02-14 | 中国医学科学院肿瘤医院肿瘤研究所 | 一种食管癌相关新基因 |
CN102119170A (zh) * | 2008-06-10 | 2011-07-06 | 肿瘤疗法科学股份有限公司 | Mybl2表位肽及包含它的疫苗 |
Non-Patent Citations (2)
Title |
---|
PER2在食管癌及癌旁组织中的差异性表达及意义;李婷婷等;《四川生理科学杂志》;20111231;第33卷(第4期);153-154 * |
Screening of specific binding peptide targeting blood vessel of human esophageal cancer in vivo in mice;ZHI M.等;《Chinese Medical Journal》;20111231;第124卷(第4期);摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN104017054A (zh) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104398526A (zh) | 雷公藤甲素和雷公藤红素在制备抗肿瘤药物中的应用 | |
Dong et al. | Curcumin enhances drug sensitivity of gemcitabine-resistant lung cancer cells and inhibits metastasis | |
CN104004056B (zh) | 一种关于Cyclin D蛋白抑制剂多肽及其应用 | |
CN104017054B (zh) | Per2蛋白激动剂多肽及其应用 | |
CN104017053B (zh) | 一种per2蛋白激动剂多肽及其应用 | |
CN104045693B (zh) | 一种关于per2蛋白激动剂多肽及其应用 | |
CN104017051B (zh) | 一种Cyclin D 蛋白抑制剂多肽及其应用 | |
CN104045689B (zh) | 一种关于生长抑素受体激动剂多肽及其应用 | |
CN104045691B (zh) | Npas2蛋白激动剂多肽及其应用 | |
CN104031128B (zh) | 一种白介素-33抑制剂多肽及其应用 | |
CN104693289A (zh) | 一种紧密连接蛋白抑制剂多肽及其应用 | |
CN104004063B (zh) | 一种关于Npas2蛋白激动剂多肽及其应用 | |
CN107095876A (zh) | 二苯基联烯基氧膦化合物在制备治疗肺癌药物中的应用 | |
CN104694520A (zh) | 一种水解纤维蛋白溶酶原多肽及其应用 | |
CN104004060B (zh) | Cyclin D蛋白抑制剂多肽及其应用 | |
CN104017052B (zh) | 关于Npas2蛋白激动剂多肽及其应用 | |
CN104693280A (zh) | 信号传导及转录激活因子抑制多肽及其应用 | |
CN102432671A (zh) | 能够抑制肝癌生长转移的靶向多肽spscvlp及用途 | |
CN104694521A (zh) | 水解纤维蛋白溶酶原多肽及其应用 | |
CN104004058B (zh) | 有关白介素-33抑制剂多肽及其应用 | |
CN104045692B (zh) | 一种Npas2蛋白激动剂多肽及其应用 | |
CN104530193A (zh) | 关于生长抑素受体激动剂多肽及其应用 | |
CN104004061B (zh) | 白介素-33抑制剂多肽及其应用 | |
CN104004062B (zh) | 关于per2蛋白激动剂多肽及其应用 | |
CN104045690A (zh) | 生长抑素受体激动剂多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Yulan Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160922 Address after: 362300 Nanan City, Fujian Province, the success of the United States Creek Industrial Zone Applicant after: NAN'AN WEISU ELECTRONIC TECHNOLOGY Co.,Ltd. Address before: High tech Zone Suzhou city Jiangsu province 215000 Chuk Yuen Road No. 209 Applicant before: SUZHOU PULUODA BIOLOGICAL SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
CB03 | Change of inventor or designer information |
Inventor after: Zhang Tao Inventor after: Sun Tao Inventor after: Chen Yulan Inventor before: Chen Yulan |
|
COR | Change of bibliographic data | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Tao Inventor after: Sun Tao Inventor after: Yang Xuefeng Inventor after: Lu Han Inventor before: Zhang Tao Inventor before: Sun Tao Inventor before: Chen Yulan |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170607 Address after: 1 building seven, building 707, 306 Jinji Road, front hill, Xiangzhou District, Zhuhai, Guangdong, 519070 Patentee after: ZHUHAI QRINIA BIOTECHNOLOGY LTD. Address before: 362300 Nanan City, Fujian Province, the success of the United States Creek Industrial Zone Patentee before: NAN'AN WEISU ELECTRONIC TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161207 |
|
CF01 | Termination of patent right due to non-payment of annual fee |